- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT03178773
TExT-MED + FANS Full Trial (TExTMED+FANSII)
14 lipca 2021 zaktualizowane przez: Elizabeth Burner, University of Southern California
Trial to EXamine Text Messaging for Diabetes in ED Patients Incorporating Social Support - Intervention With Washout
This is an intervention to study incorporating social support into mHealth interventions for low-income, ED patients with diabetes
Przegląd badań
Szczegółowy opis
Diabetes has disproportionately affected the Latino population.
TExT-MED (Trial to Examine Text Message for Emergency Department Patients with Diabetes) is a locally designed, successful mobile health (mHealth) intervention for low income Latinos with diabetes.
Social support interventions have likewise been successful at improving patient self-efficacy and disease management but are limited in scale due to two key obstacles: 1) requirements of in-person training of family and friends to be supporters and 2) the need to coordinate schedules and physical location between the patient and their supporter.
mHealth can overcome these obstacles by allowing supporters to be trained remotely via a mobile platform and by allowing communication between a patient and supporter to occur at any time or place.
The proposed intervention leverages the success of TExT-MED by augmenting the program with a social supporter that each patient can select from his or her own social support system (Family And friend Network Supporters (FANS)), creating TExT-MED+FANS.
This is a 12 month, randomized study of this intervention.
At the completion of the trial, we will evaluate the user experience with TExT-MED+FANS, and the impact of TExT-MED+FANS on patient motivation, self-efficacy and behaviors through a qualitative analysis of semi-structured individual interviews.
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
166
Faza
- Faza 2
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90033
- LAC+USC Medicine Center Emergency Department
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Age >18
- HbA1c>8.5
- Social support person identified and contacted
Exclusion Criteria:
- unable to consent
- does not speak/read English or Spanish
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Badania usług zdrowotnych
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: TExT-MED only
Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes.
A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
|
messages designed to inspire motivation and behavior change
|
|
Eksperymentalny: TExT-MED+FANS
Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes.
A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
|
messages designed to inspire motivation and behavior change
SMS delivered messages to family members to improve social support
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in HBA1c From Baseline
Ramy czasowe: 6 Months
|
Glycemic control is measured by hemoglobin A1C collected at point-of-care from an Afinion AS100 capillary point of care machine.
The Afinion machine has excellent point of care correlation with laboratory values.
As a surrogate for average glycemic control over the previous 3 months and with correlation with clinical outcomes, hemoglobin A1c is a marker of overall clinical disease management.
Change is baseline value minus follow up value.
|
6 Months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in HBA1c From 6 Months to 12 Months
Ramy czasowe: 12 months
|
Glycemic control is measured by hemoglobin A1C collected at point-of-care from an Afinion AS100 capillary point of care machine.
The Afinion machine has excellent point of care correlation with laboratory values.
As a surrogate for average glycemic control over the previous 3 months and with correlation with clinical outcomes, hemoglobin A1c is a marker of overall clinical disease management.
Change is 6 month value minus 12 month value.
|
12 months
|
|
Change in BMI From Baseline
Ramy czasowe: 6 Months
|
Calculated from Weight and Height.
As a measure of adiposity, it correlates positively with cardiovascular disease outcomes.
While imperfect, it is an easily measured and validated marker.
|
6 Months
|
|
Change in BMI From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Calculated from Weight and Height.
As a measure of adiposity, it correlates positively with cardiovascular disease outcomes.
While imperfect, it is an easily measured and validated marker.
|
12 Months
|
|
Change in Abdominal Circumference From Baseline
Ramy czasowe: 6 Months
|
A measure of central adiposity, it correlates with cardiovascular outcomes.
|
6 Months
|
|
Change From Abdominal Circumference From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
A measure of central adiposity, it correlates with cardiovascular outcomes.
|
12 Months
|
|
Change in Systolic Blood Pressure From Baseline
Ramy czasowe: 6 Months
|
Blood pressure is measured by study RAs after the patient is seated for 5 minutes, with the average of three readings used as the systolic blood pressure for that visit.
Systolic blood pressure is associated with cardiovascular complications
|
6 Months
|
|
Change in Systolic Blood Pressure From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Blood pressure is measured by study RAs after the patient is seated for 5 minutes, with the average of three readings used as the systolic blood pressure for that visit.
Systolic blood pressure is associated with cardiovascular complications
|
12 Months
|
|
Change in Diastolic Blood Pressure From Baseline
Ramy czasowe: 6 Months
|
Blood pressure is measured by study RAs after the patient is seated for 5 minutes, with the average of three readings used as the diastolic blood pressure for that visit.
|
6 Months
|
|
Change in Diastolic Blood Pressure From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Blood pressure is measured by study RAs after the patient is seated for 5 minutes, with the average of three readings used as the diastolic blood pressure for that visit.
|
12 Months
|
|
Change in Summary of Diabetes Self-care Activities From Baseline
Ramy czasowe: 6 Months
|
Summary of Diabetes Self-care Activities (Toobert, Hampson, Glasgow, & RE, 2000).
The Summary consists of 6 subscales representing different domains of diabetes related healthy behaviors and self-care.
It has been validated in over 10 studies, with the results published in two manuscripts: one with three studies (Toobert & Glasgow, 1994), and one with seven studies(Toobert et al., 2000).
Each measure ranges from Each range from 0-7, indicating number of days per week patient reports engaging in these behaviors.
|
6 Months
|
|
Change in Summary of Diabetes Self-care Activities From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Summary of Diabetes Self-care Activities (Toobert, Hampson, Glasgow, & RE, 2000).
The Summary consists of 6 subscales representing different domains of diabetes related healthy behaviors and self-care.
It has been validated in over 10 studies, with the results published in two manuscripts: one with three studies (Toobert & Glasgow, 1994), and one with seven studies(Toobert et al., 2000).
Each measure ranges from Each range from 0-7, indicating number of days per week patient reports engaging in these behaviors.
|
12 Months
|
|
Change in Wilson 3 Item Scale From Baseline
Ramy czasowe: 6 Months
|
Medication adherence(Wilson et al.,2014).
The 3item medication adherence scale is a self-report measure that assessing no. of days medication missed in prior month, days taken medication as advised & self-rated medication adherence.
Developed in HIV research, it has been validated for non-HIV medications (Wilson, et al,2016).
Each component contributes 33% of the scale.
Total score ranges from 0-100.
It is the combination of 3 sub-scores, (days missed dose(negative scored), self-rating, days taking medications as indicated).
Higher scores indicate better medication adherence.
|
6 Months
|
|
Change in Wilson 3 Item Scale From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Medication adherence(Wilson et al.,2014).
The 3item medication adherence scale is a self-report measure that assessing no. of days medication missed in prior month, days taken medication as advised & self-rated medication adherence.
Developed in HIV research, it has been validated for non-HIV medications (Wilson, et al,2016).
Each component contributes 33% of the scale.
Total score ranges from 0-100.
It is the combination of 3 sub-scores, (days missed dose(negative scored), self-rating, days taking medications as indicated).
Higher scores indicate better medication adherence.
|
12 Months
|
|
Change in Healthcare Utilization From Baseline
Ramy czasowe: 6 Months
|
Healthcare utilization by EMR review of clinic appointments, ED visits and hospitalizations within enrollment through 6 months at each follow up visit.
|
6 Months
|
|
Change in Healthcare Utilization From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Healthcare utilization by EMR review of clinic appointments, ED visits and hospitalizations within enrollment through 6 months at each follow up visit.
|
12 Months
|
|
Change in Diabetes Empowerment Scale Short Form From Baseline
Ramy czasowe: 6 Months
|
Change in Self-efficacy.
Diabetes Empowerment Scale Short Form (Anderson, Fitzgerald, Gruppen, Funnell, & Oh, 2003), is a measure of a patient's overall diabetes related self-efficacy, shortened by the original from 37 to an 8 item scale.
It has reliability of alpha=0.84; and has been shown to be sensitive to change in multiple populations and is correlated with improved glycemic control measured by A1C (Anderson et al., 2003).
It ranges from 8-40 points; higher score indicates higher self-efficacy.
|
6 Months
|
|
Change in Diabetes Empowerment Scale Short Form From 6 Months to 12 Months
Ramy czasowe: 12 months
|
Change in Self-efficacy.
Diabetes Empowerment Scale Short Form (Anderson, Fitzgerald, Gruppen, Funnell, & Oh, 2003), is a measure of a patient's overall diabetes related self-efficacy, shortened by the original from 37 to an 8 item scale.
It has reliability of alpha=0.84; and has been shown to be sensitive to change in multiple populations and is correlated with improved glycemic control measured by A1C (Anderson et al., 2003).
It ranges from 8-40 points; higher score indicates higher self-efficacy.
|
12 months
|
|
Change in Diabetes Distress Scale From Baseline
Ramy czasowe: 6 Months
|
Diabetes related distress (Diabetes Distress Scale) (Polonsky et al., 2005), is a 17 item scale measuring distress related to emotional burden, physician-related distress, regimen-related distress, and diabetes-related interpersonal issues.
It has a Cronbach's alpha of 0.88-0.93 in various studies.
Higher scores are negatively correlated with several healthy behaviors.
Each question is a Likert scale ranking of how serious a particular issue is from 1-6, 6 indicating a more significant problem.
The scores are then averaged across all item, with final scores ranging from 1-6, with 6 indicating higher levels of distress
|
6 Months
|
|
Change in Diabetes Distress Scale From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Diabetes related distress (Diabetes Distress Scale) (Polonsky et al., 2005), is a 17 item scale measuring distress related to emotional burden, physician-related distress, regimen-related distress, and diabetes-related interpersonal issues.
It has a Cronbach's alpha of 0.88-0.93 in various studies.
Higher scores are negatively correlated with several healthy behaviors.
Each question is a Likert scale ranking of how serious a particular issue is from 1-6, 6 indicating a more significant problem.
The scores are then averaged across all item, with final scores ranging from 1-6, with 6 indicating higher levels of distress
|
12 Months
|
|
Change in Patient Health Questionnaire 9 From Baseline
Ramy czasowe: 6 Months
|
Depression as measured by the PHQ-9 (Kroenke, Spitzer, Williams, & Lowe, 2010), is a widely used scale of depression used in clinical practice and research.
The Cronbach's alpha ranges from 0.86-0.89,
and it has been validated in multiple languages.
Depression is worse with higher scores.
Score ranges from 0 to 27.
Higher levels of depression are associated with fewer healthy behaviors and worse glycemic control.
|
6 Months
|
|
Change in Patient Health Questionnaire 9 From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Depression as measured by the PHQ-9 (Kroenke, Spitzer, Williams, & Lowe, 2010), is a widely used scale of depression used in clinical practice and research.
The Cronbach's alpha ranges from 0.86-0.89,
and it has been validated in multiple languages.
Depression is worse with higher scores.
Score ranges from 0 to 27.
Higher levels of depression are associated with fewer healthy behaviors and worse glycemic control.
|
12 Months
|
|
Change in Fatalism From Baseline
Ramy czasowe: 6 Months
|
Fatalism is measured by the Diabetes Fatalism Scale (Egede & Ellis, 2010), which measures three subscale emotional distress, religiosity and coping and perceived self-efficacy, which are summed together.
The total score ranges from 12-72, higher score indicates higher fatalism, and has a Cronbach's alpha of 0.80.
The score is associated with glycemic control, depression, self-care behaviors and social factors.
|
6 Months
|
|
Change in Fatalism From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Fatalism is measured by the Diabetes Fatalism Scale (Egede & Ellis, 2010), which measures three subscale emotional distress, religiosity and coping and perceived self-efficacy, which are summed together.
The total score ranges from 12-72, higher score indicates higher fatalism, and has a Cronbach's alpha of 0.80.
The score is associated with glycemic control, depression, self-care behaviors and social factors.
|
12 Months
|
|
Change in WHO Quality of Life From Baseline
Ramy czasowe: 6 Months
|
Quality of life (World Health Organization WHO-5 Well Being Index) (Topp, Ostergaard, Sondergaard, & Bech, 2015) is a widely used measure of quality life, validated in many languages and consists of only 5 items.
Each self-reported item is scored between 0 and 5, summed together and then multiplied by 4. The total range is from 0 to 100, with 0 being the lowest quality of life.
|
6 Months
|
|
Change in WHO Quality of Life From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Quality of life (World Health Organization WHO-5 Well Being Index) (Topp, Ostergaard, Sondergaard, & Bech, 2015) is a widely used measure of quality life, validated in many languages and consists of only 5 items.
Each self-reported item is scored between 0 and 5, summed together and then multiplied by 4. The total range is from 0 to 100, with 0 being the lowest quality of life.
|
12 Months
|
|
Change in Diabetes Family Behavior Checklist - Supportive From Baseline
Ramy czasowe: 6 Months
|
Diabetes-related supportive and obstructive family behaviors are measured by patient report on the Diabetes Family Behavior checklist (Lewin et al., 2005).
Family behaviors: supportive and non-supportive sub-scores of the Diabetes Family Behavior Checklist: supportive ranges from 4-45 (4 being lowest in family supportive behavior), non-supportive ranges from 7-35 (4 indicating least report of non-supportive behavior).
Non-supportive scores are subtracted form supportive scores for a total.
|
6 Months
|
|
Change in Diabetes Family Behavior Checklist Supportive From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Diabetes-related supportive and obstructive family behaviors are measured by patient report on the Diabetes Family Behavior checklist (Lewin et al., 2005).
Family behaviors: supportive and non-supportive sub-scores of the Diabetes Family Behavior Checklist: supportive ranges from 4-45 (4 being lowest in family supportive behavior), non-supportive ranges from 7-35 (4 indicating least report of non-supportive behavior).
Non-supportive scores are subtracted form supportive scores for a total.
|
12 Months
|
|
Change in Diabetes Family Behavior Checklist - Nonsupportive From Baseline
Ramy czasowe: 6 Months
|
Diabetes-related supportive and obstructive family behaviors are measured by patient report on the Diabetes Family Behavior checklist (Lewin et al., 2005).
Family behaviors: supportive and non-supportive sub-scores of the Diabetes Family Behavior Checklist: supportive ranges from 4-45 (4 being lowest in family supportive behavior), non-supportive ranges from 7-35 (4 indicating least report of non-supportive behavior).
Non-supportive scores are subtracted form supportive scores for a total.
|
6 Months
|
|
Change in Diabetes Family Behavior Checklist Nonsupportive From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Diabetes-related supportive and obstructive family behaviors are measured by patient report on the Diabetes Family Behavior checklist (Lewin et al., 2005).
Family behaviors: supportive and non-supportive sub-scores of the Diabetes Family Behavior Checklist: supportive ranges from 4-45 (4 being lowest in family supportive behavior), non-supportive ranges from 7-35 (4 indicating least report of non-supportive behavior).
Non-supportive scores are subtracted form supportive scores for a total.
|
12 Months
|
|
Change in Diabetes Care Profile Support From Baseline
Ramy czasowe: 6 Months
|
Diabetes-specific social support is measured by the Diabetes Care Profile Support Questions,(Fitzgerald et al., 1996) with sub-scores for perceived disease specific support needs and perceived disease specific support received.
Diabetes Care Profile support questions: Support wanted, and support received.
Each range from 5 to 30, high scores indicating high desire for support and higher support received.
|
6 Months
|
|
Change in Diabetes Care Profile Support From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Diabetes-specific social support is measured by the Diabetes Care Profile Support Questions,(Fitzgerald et al., 1996) with sub-scores for perceived disease specific support needs and perceived disease specific support received.
Diabetes Care Profile support questions: Support wanted, and support received.
Each range from 5 to 30, high scores indicating high desire for support and higher support received.
|
12 Months
|
|
Change in Norbeck Social Support Questionnaire From Baseline
Ramy czasowe: 6 Months
|
Measure Description: General social support is captured by the Norbeck Social Support Questionnaire Emotional and&Tangible subscales.(Norbeck,
Lindsey, & Carrieri, 1981) General social support: Norbeck Social Support Questionnaire, emotional sub score (ranges 0-16, with higher scores indicating higher perceived emotional support) & tangible sub score (0-8, higher score indicating higher perceived tangible support).
While the subscores are highly correlated, the authors do not recommend Cronbach's alpha as a test of internal validity.(http://eileengigliotti.com/uploads/1/1/0/2/110241155/nssq-psychometric.pdf)
|
6 Months
|
|
Change in Norbeck Social Support Questionnaire From 6 Months to 12 Months
Ramy czasowe: 12 Months
|
Measure Description: General social support is captured by the Norbeck Social Support Questionnaire Emotional and&Tangible subscales.(Norbeck,
Lindsey, & Carrieri, 1981) General social support: Norbeck Social Support Questionnaire, emotional sub score (ranges 0-16, with higher scores indicating higher perceived emotional support) & tangible sub score (0-8, higher score indicating higher perceived tangible support).
While the subscores are highly correlated, the authors do not recommend Cronbach's alpha as a test of internal validity.(http://eileengigliotti.com/uploads/1/1/0/2/110241155/nssq-psychometric.pdf)
|
12 Months
|
|
Change in Partner Distress Scale From Baseline
Ramy czasowe: 6 Months
|
Supporter diabetes-related distress is measured by the Partner Distress Scale (Polonsky, Fisher, Hessler, &Johnson, 2016).
The self-report scale consists of 21 items in 4 domains: "my partner's diabetes management", "how best to help", "diabetes & me", & "hypoglycemia".
Domains are summed together.
Each item is score from 0 to 4, lower scores indicate less distress.
The total score is an average of the 21 items.
The Cronbach's alpha was 0.76 for total scores.
Greater partner distress is correlated with higher A1C among patients, worse self-care & lower satisfaction with relationship
|
6 Months
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
18 lipca 2017
Zakończenie podstawowe (Rzeczywisty)
2 grudnia 2019
Ukończenie studiów (Rzeczywisty)
2 grudnia 2019
Daty rejestracji na studia
Pierwszy przesłany
5 czerwca 2017
Pierwszy przesłany, który spełnia kryteria kontroli jakości
5 czerwca 2017
Pierwszy wysłany (Rzeczywisty)
7 czerwca 2017
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
6 sierpnia 2021
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
14 lipca 2021
Ostatnia weryfikacja
1 lipca 2021
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- HS-17-00406
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
NIE
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Cukrzyca
-
National Center for Research Resources (NCRR)Northwestern UniversityZakończonyMoczówka prosta | Diabetes Insipidus, NeurohypophysealStany Zjednoczone
-
University of BernDexCom, Inc.; DCB Research AG; mylife Diabetes Care AGRekrutacyjny
-
Children's Hospital of Fudan UniversityRekrutacyjnyKopeptyna | Diabetes Insipidus, Neurohypophyseal | Interwencja neurochirurgiczna | Poziomy kopeptyny we krwiChiny
-
Leiden University Medical CenterZakończonyGruczolak przysadki | Guz przysadki | Diabetes Insipidus Cranial Type | Dokrewny; NiedobórHolandia
-
University Hospital, Basel, SwitzerlandRekrutacyjnyTechnologia Sonic AfitmmentationSzwajcaria
-
Ferring PharmaceuticalsZakończonyCentralna moczówka prostaJaponia
-
University Hospital, Basel, SwitzerlandRekrutacyjnyMoczówka prosta | Niedobór AVPSzwajcaria
-
Universitair Ziekenhuis BrusselZakończonyNefrogenna moczówka prostaBelgia
-
Emory UniversityZakończony
-
National Center for Research Resources (NCRR)Northwestern UniversityZakończonyDiabetes Insipidus, nefrogenny
Badania kliniczne na TExT-MED
-
Vanderbilt University Medical CenterZakończonyNiepewna żywnośćStany Zjednoczone
-
Taipei Medical UniversityZakończony
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI)Aktywny, nie rekrutującyChoroby przewlekłe, wielokrotneStany Zjednoczone
-
Yale UniversityZakończonyRak piersi | Adhezja, lekarstwo | Efekt ubocznyStany Zjednoczone
-
Pulse TherapeuticsZawieszonyZaburzenia naczyniowo-mózgowe | Zaburzenia neurologiczne | Zawał, tętnica środkowa mózgu | Udar, niedokrwienny | Udar, ostry | Zator wewnątrzczaszkowy i zakrzepica | Udary zakrzepoweZjednoczone Królestwo
-
Rambam Health Care CampusZakończony
-
South Eastern Health and Social Care TrustZakończonyPrzewlekła obturacyjna choroba płucZjednoczone Królestwo
-
USDA Grand Forks Human Nutrition Research CenterEgg Nutrition CenterZakończony
-
University of North Carolina, Chapel HillCenters for Disease Control and PreventionZakończony
-
Fondazione Policlinico Universitario Agostino Gemelli...Rekrutacyjny